Rigosertib data presented at EADV Congress 2023

Data on the use of rigosertib in patients with RDEB-associated squamous cell carcinoma was presented at the European Academy of Dermatology and Venerology (EADV) Congress last week.

The abstract outlines the treatment of four patients with either intravenous or oral rigosertib, as part of an open-label clinical trial. Of the four patients, two achieved complete cutaneous responses of 12 months or more, one patient experienced metastatic disease progression, and one patient remains in the study.

EB-associated squamous cell carcinoma is a leading cause of premature death in patients with RDEB. Cure EB is co-funding this promising work – funding one patient in the US and up to three patients in the UK. Read more about the trial.